stockrowAnaptysBio, Inc.
ANAB Healthcare Biotechnology
AnaptysBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $234.6 million, up 157.0% from fiscal 2024.
- Revenue
- −7.98%
- EPS
- −43.8%
- Free cash flow
- −141.6%
Quarter to March 2026, against a year earlier
Follow ANAB
Alert me
AnaptysBio, Inc. (ANAB) EV/Sales
As of 6 November 2026, AnaptysBio, Inc. (ANAB) trades at a EV/Sales of 4.5×. Over the past ten years it has ranged from −11.8× (November 2019) to 90.7× (March 2018); the current reading is higher than 61% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.6× | — |
| FY2024 | −1.5× | — |
| FY2023 | 0.0× | (99.99%) |
| FY2022 | 10.5× | 656.83% |
| FY2021 | 1.4× | — |
| FY2020 | 0.0× | — |
| FY2019 | −5.0× | — |
| FY2018 | 35.0× | (48.31%) |
| FY2017 | 67.7× | — |
| FY2016 | −0.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 3.3× | 26.47% |
| Dec 2025 | 2.6× | 39.36% |
| Sep 2025 | 1.9× | 43.68% |
| Jun 2025 | 1.3× | 256.70% |
| 28 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | n/m |
| MLYS Mineralys Therapeutics, Inc. compare | n/m |
| KARD KARDIGAN INC compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| DMRA Galecto, Inc. compare | n/m |
| ANAB AnaptysBio, Inc. | 4.5× |
| KRSA Korsana Biosciences, Inc. compare | 8.3× |
| OCUL Ocular Therapeutix, Inc. compare | 18.5× |
| TSHA Taysha Gene Therapies, Inc. compare | 102× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)